Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Research

Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway

Authors: Zhuling Qu, He Dong, Xiaolin Xu, Wei Feng, Xuanlong Yi

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Objective

The tumor necrosis factor (TNF) and the cellular NF-κB pathway protein IKKβ play important roles in various cellular processes such as cell proliferation, survival, differentiation, and apoptosis. A heat shock protein 90 inhibitor, 17-DMAG, can induce apoptosis of some tumor cells. This study is to determine the combined effects of 17-DMAG and TNF on malignant cells and the related mechanisms.

Methods

We have determined effects of 17-DMAG, an Hsp90 inhibitor, and TNF treatments on the small cell lung cancer cell line (MS-1), the adenocarcinoma cell line (A549), the squamous-cell carcinoma cell line (LK-2), and the normal human bronchial epithelium cell line (NuLi-1) by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrozolium bromide assay. To determine if 17-DMAG inhibit the expression of IKKβ in the normal human NuLi-1 cells, and the malignant MS-1, A549, and LK-2 cells, immunoblotting assays and luciferase assays were performed.

Results

It was found that the combined treatments resulted in synergistic killing of malignant cells, which was confirmed by the apoptosis determination using a fluorescence microscopic assay following staining of the drug-treated cells with Hoescht 33258. The immunoblotting results indicated that the synergistic killing due to 17-DMAG and TNF treatments may be related to the decreases in IKKβ levels in the presence of 17-DMAG.

Conclusions

The results suggest that combination of 17-DMAG and TNF treatments might be useful for treating malignancies upon further study in the further.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​2041198513886824​
Appendix
Available only for authorised users
Literature
1.
Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997, 90: 65-75. 10.1016/S0092-8674(00)80314-1.CrossRefPubMed
2.
da Silva VC, Ramos CH: The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J Proteomics. 2012, 75: 2790-2802. 10.1016/j.jprot.2011.12.028.CrossRefPubMed
3.
Taipale M, Jarosz DF, Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010, 11: 515-528. 10.1038/nrm2918.CrossRefPubMed
4.
Theodoraki MA, Caplan AJ: Quality control and fate determination of Hsp90 client proteins. Biochim Biophys Acta. 1823, 2012: 683-688.
5.
Holzbeierlein JM, Windsperger A, Vielhauer G: Hsp90: a drug target?. Curr Oncol Rep. 2010, 12: 95-101. 10.1007/s11912-010-0086-3.CrossRefPubMed
6.
Pacey S, Banerji U, Judson I, Workman P: Hsp90 inhibitors in the clinic. Handb Exp Pharmacol. 2006, 172: 331-358. 10.1007/3-540-29717-0_14.CrossRefPubMed
7.
Neckers L, Ivy SP: Heat shock protein 90. Curr Opin Oncol. 2003, 15: 419-424. 10.1097/00001622-200311000-00003.CrossRefPubMed
8.
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003, 425: 407-410. 10.1038/nature01913.CrossRefPubMed
9.
Aggarwal BB: Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003, 3: 745-756. 10.1038/nri1184.CrossRefPubMed
10.
Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 2003, 10: 45-65. 10.1038/sj.cdd.4401189.CrossRefPubMed
11.
Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P: The death domain kinase RIP mediates the TNF-induced NF-nB signal. Immunity. 1998, 8: 297-303. 10.1016/S1074-7613(00)80535-X.CrossRefPubMed
12.
Ting AT, Pimentel-Muinos FX, Seed B: RIP mediates tumor necrosis factor receptor 1 activation of NF-nB but not Fas/APO-1-initiated apoptosis. EMBO J. 1996, 15: 6189-6196.PubMedCentralPubMed
13.
Zhang J, Winoto A: A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol Cell Biol. 1996, 16: 2756-2763.PubMedCentralCrossRefPubMed
14.
Karin M, Yamamoto Y, Wang QM: The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3: 17-26. 10.1038/nrd1279.CrossRefPubMed
15.
Yang J, Lin Y, Guo Z: The essential role of MEKK3 in TNF-induced NFκB activation. Nat Immunol. 2001, 2: 620-624.CrossRefPubMed
16.
Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF: IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science. 1998, 281: 998-1001.CrossRefPubMed
17.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NFκB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998, 281: 1680-1683.CrossRefPubMed
18.
Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M: Reactive oxygen species promote TNFa induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005, 120: 649-661. 10.1016/j.cell.2004.12.041.CrossRefPubMed
19.
Broemer M, Krappmann D, Scheidereit C: Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene. 2004, 23: 5378-5386. 10.1038/sj.onc.1207705.CrossRefPubMed
20.
Lewis J, Devin A, Miller A: Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-κB activation. J Biol Chem. 2000, 275: 10519-10526. 10.1074/jbc.275.14.10519.CrossRefPubMed
21.
Fukumoto R, Kiang JG: Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation. Radiat Res. 2011, 176: 333-345. 10.1667/RR2534.1.PubMedCentralCrossRefPubMed
22.
Lancet JE, Gojo I, Burton M: Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010, 24: 699-705. 10.1038/leu.2009.292.CrossRefPubMed
23.
Jhaveri K, Miller K, Rosen L: A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clin Cancer Res. 2012, Epub ahead of print
24.
Palacios C, Martín-Pérez R, López-Pérez AI, Pandiella A, López-Rivas A: Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res. 2010, 34: 1533-1538. 10.1016/j.leukres.2010.07.002.CrossRefPubMed
25.
Zheng N, Zou P, Wang S, Sun D: In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes. Drug Metab Dispos. 2011, 39: 627-635. 10.1124/dmd.110.036418.PubMedCentralCrossRefPubMed
26.
Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S: Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol. 1989, 9: 3919-3930.PubMedCentralCrossRefPubMed
27.
Akner G, Mossberg K, Sundqvist KG, Gustafsson JA, Wikstrom AC: Evidence for reversible, non-microtubule and non-microfilament-dependent nuclear translocation of hsp90 after heat shock in human fibroblasts. Eur J Cell Biol. 1992, 58: 356-364.PubMed
28.
Biggiogera M, Tanguay RM, Marin R, Wu Y, Martin TE, Fakan S: Localization of heat shock proteins in mouse male germ cells: an immunoelectron microscopical study. Exp Cell Res. 1996, 229: 77-85. 10.1006/excr.1996.0345.CrossRefPubMed
29.
Langer T, Rosmus S, Fasold H: Intracellular localization of the 90 kDA heat shock protein (HSP90α) determined by expression of a EGFP-HSP90α-fusion protein in unstressed and heat stressed 3T3 cells. Cell Biol Int. 2003, 27: 47-52. 10.1016/S1065-6995(02)00256-1.CrossRefPubMed
30.
Pratt WB, Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997, 18: 306-360. 10.1210/er.18.3.306.PubMed
31.
Pearl LH, Prodromou C: Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 2006, 75: 271-294. 10.1146/annurev.biochem.75.103004.142738.CrossRefPubMed
32.
Whitesell L, Lindquist SL: HSP90 and the chaperoning of cancer. Nature Rev Cancer. 2005, 5: 761-772. 10.1038/nrc1716.CrossRef
33.
Keane MM, Rubinstein Y, Cuello M: Inhibition of NF-nB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat. 2000, 64: 211-219. 10.1023/A:1006458407515.CrossRefPubMed
34.
Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsunoda S: Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines. Diagn Pathol. 2010, 5: 41-10.1186/1746-1596-5-41.PubMedCentralCrossRefPubMed
35.
Lal A, Panos R, Marjanovic M, Walker M, Fuentes E, Kubicek GJ: A gene expression profile test to resolve head & neck squamous versus lung squamous cancers. Diagn Pathol. 2013, 8: 44-10.1186/1746-1596-8-44.PubMedCentralCrossRefPubMed
Metadata
Title
Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway
Authors
Zhuling Qu
He Dong
Xiaolin Xu
Wei Feng
Xuanlong Yi
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-70

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue

Research

The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis

Research

Long-term analysis to objectify the tumour grading by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) in the case of breast carcinoma

Research

Analysis of HAX-1 gene expression in esophageal squamous cell carcinoma

Research

Polymorphous low-grade adenocarcinoma: an analysis of epidemiological studies and hints for pathologists

Research

Dramatic early event in chronic allograft nephropathy: increased but not decreased expression of MMP-9 gene

Research

An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas